GE HealthCare announced it has entered into an agreement to acquire Intelerad, a leading medical imaging software provider for the healthcare industry, for a purchase price of $2.3 billion paid in cash. This acquisition demonstrates GE HealthCare’s continued commitment to cloud-enabled and AI-powered solutions across care settings and furthers the company’s aim to triple its offerings of cloud-enabled products by 2028..

GE医疗宣布已达成协议，将以23亿美元现金收购医疗行业领先的医学影像软件供应商Intelerad。此次收购展示了GE医疗对云技术和人工智能解决方案在各类护理场景中的持续承诺，并推动了公司到2028年将其云技术支持的产品数量增加三倍的目标。

Intelerad is a leading medical imaging software and digital enterprise workflow solutions company with a significant presence in outpatient ambulatory care settings. Its cloud-first products are designed for radiology and cardiology and extend across both inpatient and outpatient care settings. Intelerad’s leading outpatient footprint complements GE HealthCare’s leadership in hospital-based imaging.

Intelerad是一家领先的医疗影像软件和数字化企业工作流程解决方案公司，在门诊护理领域有着显著的影响力。其以云端为优先的产品专为放射学和心脏病学设计，涵盖住院和门诊护理环境。Intelerad领先的门诊业务足迹与GE HealthCare在医院影像领域的领导地位形成互补。

Together, these combined capabilities will create a more comprehensive, cloud-first and AI-enabled imaging offering spanning diverse care settings—from large academic medical centers to rapidly expanding ambulatory networks..

这些综合能力将创造一个更全面、以云为优先、支持人工智能的影像服务，涵盖从大型学术医疗中心到快速扩展的门诊网络等不同的护理环境。

'As hospital and ambulatory care providers face increased demand for imaging and rising patient volumes, they are looking to simplify and unify their workflows,' said Peter Arduini, President and CEO of GE HealthCare. 'Our acquisition of Intelerad will bring additional cloud-enabled and intelligent solutions in radiology and cardiology into our portfolio of products and extend our capabilities into outpatient networks, enabling care teams to be more efficient, improve outcomes, and deliver precision care for patients globally.

“随着医院和门诊护理供应商面临日益增长的影像需求和患者数量，他们正在寻求简化并统一其工作流程，”GE HealthCare总裁兼首席执行官彼得·阿尔杜尼表示。“我们对Intelerad的收购将为我们的产品组合引入更多基于云端且智能化的放射学和心脏病学解决方案，并将我们的能力扩展到门诊网络，帮助医护团队提高效率、改善治疗效果，并为全球患者提供精准护理。”

As a result, we expect to accelerate our growth in SaaS products and recurring revenues as we take another evolutionary step to grow into a healthcare solutions provider.”.

因此，随着我们向成为医疗解决方案提供商迈出又一步，我们预计将加快我们在SaaS产品和经常性收入方面的增长。”

“Intelerad is an outstanding strategic fit and is a pioneer in cloud-based imaging software, with a strong portfolio of world-class solutions across care settings. By combining GE HealthCare’s medical device and AI competence at global scale with Intelerad’s enterprise cloud and imaging expertise, we will be even better positioned to meet the evolving needs of healthcare providers, simplify complex workflows, and drive digital innovation across the industry,” said Roland Rott, President and CEO of Imaging at GE HealthCare..

“Intelerad 是一项出色的战略契合，同时也是基于云的影像软件领域的先锋，拥有覆盖各类护理环境的世界级解决方案的强大组合。通过将 GE HealthCare 的全球医疗设备和人工智能能力与 Intelerad 的企业云和影像技术专长相结合，我们将能够更好地满足医疗服务提供者不断变化的需求，简化复杂的工作流程，并推动整个行业的数字化创新，”GE HealthCare 影像业务总裁兼首席执行官罗兰·罗特 (Roland Rott) 表示。

“Joining GE HealthCare marks an exciting new chapter for Intelerad. GE HealthCare’s global scale and extensive relationships with key decision makers across hospital systems will fuel the expansion of our connected imaging software offering. Together, we look forward to advancing digital innovation in healthcare and delivering more integrated AI-enabled solutions that empower our customers to tackle their greatest challenges,” said Jordan Bazinsky, the CEO of Intelerad..

“加入GE HealthCare标志着Intelerad令人兴奋的新篇章。GE HealthCare的全球规模以及与医院系统关键决策者广泛的关系，将推动我们互联影像软件产品的扩展。我们期待共同推动医疗保健领域的数字化创新，提供更加集成的AI赋能解决方案，助力客户应对他们面临的最大挑战，”Intelerad首席执行官Jordan Bazinsky表示。

Benefits of the Transaction

交易的好处

Accelerates GE HealthCare’s Digital Transformation

加速GE医疗的数字化转型

The acquisition is highly complementary to GE HealthCare’s prominent inpatient footprint by expanding to outpatient and ambulatory care settings. By harnessing these two complementary and scaled product offerings, the combined business will broaden customer reach and delivers a comprehensive, integrated imaging solution across multiple care settings.

此次收购通过扩展到门诊和流动护理环境，对GE HealthCare突出的住院业务具有高度互补性。通过整合这两项互补且规模化的产线，合并后的业务将扩大客户覆盖范围，并在多种护理环境中提供全面、集成的成像解决方案。

In addition, Intelerad’s business model accelerates GE HealthCare’s shift towards a SaaS model and significantly increases recurring revenue..

此外，Intelerad 的业务模式加速了 GE HealthCare 向 SaaS 模式的转变，并显著增加了经常性收入。

Enables GE HealthCare to expand into a $2 billion-plus growth segment

使GE医疗能够扩展到一个价值20亿美元以上的增长领域

Outpatient enterprise imaging presents an attractive high-growth, $2 billion-plus opportunity for GE HealthCare worldwide. Cloud-based or cloud-native solutions are expected to grow at a double-digit rate in the medium term driven by accelerating global cloud and SaaS adoption, procedure shift to outpatient settings, and demand for integrated solutions that can increase operating efficiencies..

门诊企业影像业务为GE医疗在全球范围内提供了一个极具吸引力的高增长、超过20亿美元的机会。基于云或云原生的解决方案预计将在中期内以两位数的速度增长，这得益于全球云和SaaS采用的加速、手术向门诊环境的转移，以及对能够提高运营效率的集成化解决方案的需求驱动。

Delivers Highly Attractive Financial Benefits

提供极具吸引力的财务效益

GE HealthCare estimates that Intelerad’s revenues in the first full year of ownership will be approximately $270 million, of which approximately 90% is recurring, and Adjusted Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) margin will be in excess of 30%. Intelerad revenue is growing in the low-double-digit range annually and is expected to accelerate under GE HealthCare in the combined entity.

GE医疗估计，在完全拥有的第一年，Intelerad的收入将约为2.7亿美元，其中约90%为经常性收入，调整后的息税折旧摊销前利润（EBITDA）率将超过30%。Intelerad的收入每年以低两位数的百分比增长，并预计在与GE医疗合并后将进一步加速。

Upon close, GE HealthCare expects this transaction to be immediately accretive to top line growth and Adjusted Earnings Before Interest and Taxes (EBIT) margin1. Inclusive of the impact of financing costs, GE HealthCare expects the transaction to be slightly dilutive to Adjusted Earnings Per Share (EPS)1 in the short term, and the company plans to offset this with cost efficiencies.

在交易完成时，GE医疗预计该交易将立即对营收增长和调整后的息税前利润（EBIT）率产生积极影响。考虑到融资成本的影响，GE医疗预计该交易短期内将对调整后的每股收益（EPS）略有稀释，公司计划通过成本效率来抵消这一影响。

GE HealthCare expects a high-single-digit return on invested capital by year five..

GE医疗预计到第五年将实现高个位数的投资资本回报率。

Approvals and Financing

批准与融资

The transaction is expected to be completed in the first half of 2026, subject to customary closing conditions and regulatory approvals. GE HealthCare intends to fund this transaction with cash on hand and proceeds from debt financing.

该交易预计将于2026年上半年完成，但需满足惯例的交割条件并获得监管机构的批准。GE HealthCare打算通过手头现金和债务融资所得来为这笔交易提供资金。

Advisors

顾问

For GE HealthCare, Evercore is serving as exclusive financial advisor and Sidley Austin LLP as deal counsel. For Intelerad, UBS Investment Bank is serving as exclusive financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP as deal counsel.

对于GE HealthCare，Evercore担任独家财务顾问，Sidley Austin LLP担任交易法律顾问。对于Intelerad，UBS投资银行担任独家财务顾问，Skadden, Arps, Slate, Meagher & Flom LLP担任交易法律顾问。

Additional Background

额外背景

Founded in Montreal, Canada in 1999 with operations in the U.S. and Canada, Intelerad is a privately held medical imaging software provider. GE HealthCare looks forward to collaborating with Intelerad’s employee teams and partners and investing in their success.

总部位于加拿大蒙特利尔的 Intelerad 是一家私营医疗影像软件供应商，于 1999 年在加拿大成立，业务遍及美国和加拿大。GE HealthCare 期待与 Intelerad 的员工团队和合作伙伴合作，投资于他们的成功。

Intelerad specializes in diagnostic viewing, reporting, archiving, and collaboration tools for healthcare providers. Their products offer modern, scalable, and integrated end-to-end technical architecture. Intelerad’s solutions also include a breadth of enterprise imaging solutions for the ambulatory and acute care segments across sub-specialties.

Intelerad 专注于为医疗保健提供者提供诊断查看、报告、存档和协作工具。其产品提供现代化、可扩展且集成的端到端技术架构。Intelerad 的解决方案还包括针对门诊和急症护理领域各亚专科的广泛企业影像解决方案。

Over 1,500 healthcare organizations around the world rely on Intelerad products to manage patient data, improve imaging efficiency and quality, and elevate patient outcomes..

全球超过 1,500 家医疗机构依靠 Intelerad 产品来管理患者数据、提高影像效率和质量，并提升患者治疗效果。

As a result of the transaction, Hg Capital, Intelerad’s majority shareholder, and TA Associates, an investor since 2022, will fully exit their investments in the company.

作为交易的结果，Hg Capital（Intelerad 的多数股东）和自 2022 年以来的投资者 TA Associates 将完全退出他们在该公司的投资。

Forward-Looking Statements

前瞻性声明

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” “forecast,” “target,” “guidance,” “outlook,” and similar expressions.

本发布包含前瞻性陈述。这些前瞻性陈述可以通过词语及词语变体来识别，例如“将”、“预期”、“可能”、“会”、“能够”、“计划”、“相信”、“预计”、“意图”、“估计”、“潜力”、“定位”、“预测”、“目标”、“指引”、“展望”以及类似表达。

These forward-looking statements may include, but are not limited to, statements about the transaction, the completion and expected results of the transaction, and GE HealthCare Technologies Inc.’s (the “Company’s”) markets, business, products, financial performance, growth opportunities, and strategy.

这些前瞻性声明可能包括但不限于关于交易、交易的完成及预期结果，以及GE医疗技术公司（“公司”）的市场、业务、产品、财务表现、增长机会和战略的声明。

These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the conditions to the completion of the transaction may not be satisfied; closing of the transaction may not occur or may be delayed; the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; the Company may assume unexpected risks and liabilities; and completing the transaction may distract the Company’s management from other important matters.

这些前瞻性陈述涉及风险和不确定性，其中许多是公司无法控制的。可能导致公司实际结果与前瞻性陈述中所述内容存在重大差异的因素包括但不限于：完成交易的条件可能无法满足；交易可能无法完成或被延迟；公司可能无法实现交易的预期效益；运营成本和业务中断（包括但不限于难以维持与员工、客户和供应商的关系）可能超出预期；公司可能承担意外的风险和责任；完成交易可能分散公司管理层对其他重要事项的注意力。

Other factors that may cause such a difference also include those discussed in the 'Risk Factors' section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the.

可能导致这种差异的其他因素还包括公司在提交给美国证券交易委员会的10-K表格年报中的“风险因素”部分讨论的内容，以及其在未来文件中所做的任何更新或修订。可能还存在其他目前未知的因素。

About GE HealthCare Technologies Inc.

关于GE HealthCare Technologies Inc.

GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier.

GE HealthCare是一家值得信赖的合作伙伴和领先的全球医疗保健解决方案提供商，创新医疗技术、药物诊断以及集成的、以云为优先的人工智能解决方案、服务和数据分析。我们的目标是提高医院和卫生系统的效率，增强临床医生的工作效果，使治疗更加精准，并让患者更健康、更快乐。

Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring.

服务患者和医疗机构超过125年的GE医疗集团，正在推进个性化、互联和富有同情心的医疗服务，同时简化患者在治疗过程中的旅程。我们的影像、高级可视化解决方案、患者护理解决方案和药物诊断业务共同协作，帮助改善从筛查、诊断到治疗和监测的整个患者护理流程。

We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits..

我们是一家价值 197 亿美元的企业，拥有大约 53,000 名同事，致力于创造一个医疗保健没有限制的世界。

GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.

GE HealthCare 很荣幸被评为 2025 年《财富》世界最受赞赏公司™之一。

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

请在LinkedIn、X、Facebook、Instagram和Insights上关注我们以获取最新消息，或访问我们的网站https://www.gehealthcare.com了解更多信息。

1 Non-GAAP financial measure; see our earnings release dated October 29, 2025 for definition.

1 非GAAP财务指标；定义请参见我们于2025年10月29日发布的财报。

GE HealthCare Investor Relations Contact:

GE医疗投资者关系联系人：

Carolynne Borders

卡罗琳·鲍德斯

[email protected]

电子邮件地址

M (631) 662-4317

M (631) 662-4317

GE HealthCare Media Contact:

GE医疗媒体联系人：

Linh Dinh

林丁

[email protected]

电子邮件地址

M +408 275 5682

M +408 275 5682

Source: gehealthcare.com

来源：gehealthcare.com